No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

Figure 2

Clinical outcome stratified by the CD33 rs12459419 polymorphism for patients treated with GO during the consolidation phase (a–h). (a) Overall survival (OS). (b) Relapse-free survival (RFS). (c–h) OS and RFS according to CD33 rs12459419 polymorphism and genetic risk. (c and d) OS and RFS in the favorable group; (e and f) OS and RFS in the intermediate group; and (g and h) OS and RFS in the adverse group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)